Topics Companies

 
News Articles for Topics Companies top ^
2014/8/27
23.8% of Topical T subjects below 10 million sperm/mL at end of study versus 2.3% and 2.4% respectively for Androxal ® and placebo ITT (Androxal ® vs.
Sign-up for Androxal(R) Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints and Various Secondary Endpoints Versus Marketed Topical Gel in First of Two Identical Studies in the Treatment of Secondary Hypogonadism investment picks
2014/9/25
44.2% of Topical T subjects below 10 million sperm/mL at end of study versus 2.4% and 0.0% respectively for Androxal ® and placebo ITT (Androxal ® vs.
Sign-up for Androxal(R) Second Pivotal Study Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints Versus Marketed Topical Gel in the Treatment of Secondary Hypogonadism investment picks
DUBLIN , July 30, 2014 /PRNewswire/ -- Perrigo Company (NYSE: PRGO;TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application for desoximetasone topical spray 0.25% and that it has notified Taro Pharmaceuticals U.S.A. , Inc., the owner of the Reference Listed Drug of its filing.
Sign-up for Perrigo Confirms First To File Patent Challenge For Generic Version Of Topicort® Topical Spray 0.25% investment picks
Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) today announced the U.S. launch of Anacor’s FDA-approved drug KERYDIN TM (tavaborole) topical solution, 5% by Sandoz Inc., a Novartis company.
Sign-up for Anacor Pharmaceuticals Announces Commercial Launch of KERYDIN (tavaborole) Topical Solution, 5% in the United States investment picks
Schedule for study completion remains unaffected Company anticipates submission of NDA by year end 2014 THE WOODLANDS, Texas, July 16, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq:RPRX) today announced it has received additional guidance from the FDA regarding primary endpoints for the two studies, ZA-304 and ZA-305, that it is currently conducting comparing Androxal ® to the leading approved testosterone gel and placebo.
Sign-up for FDA Confirms Sperm and Testosterone Endpoints as Key Parameters for Assessment of Androxal(R) Versus Approved Topical Gel and Placebo investment picks
http://media.marketwire.com/attachments/201409/TN-278707_Apricus-Biosciences-Richard-Pascoe-1800publicrelations-1800pr.jpg Apricus Biosciences, Inc. CEO Richard Pascoe Public Relations by 1800PublicRelations.com http://media.marketwire.com/attachments/201409/TN-278708_1800-office-space-image-OS-Lumbergh-coffee8copy.jpg Public Relations and Marketing by 1800PublicRelations.com http://media.marketwire.com/attachments/201409/278706_Apricus-Biosciences-Logo-1800publicrelations-1800pr.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1147027&ProfileId=051205&sourceType=1 DALLAS, TX and SAN DIEGO, CA --
Sign-up for Apricus CEO to Discuss Company's Drug Portfolio, Including Its Topical Cream for Erectile Dysfunction, Vitaros(R), LIVE on iHeart (Clear Channel) Business Talk Radio DFW 1190AM on Sept. 25, 2014 investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Topics Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Topeka Capital Markets  |  Next: Topline Results